Epilepsy: Epidemiology and Patient-Based Market Forecasts, Treatment Algorithm, and Marketed and Pipeline Drug Analysis

  • ID: 3797415
  • Drug Pipelines
  • 326 pages
  • Datamonitor Healthcare
1 of 3
Refractory patients, niche indication expansions, and geographical reach offer room for growth in an otherwise crowded epilepsy market.

This report addresses the following questions:

- Why do leading antiepileptic drugs retain a large amount of brand loyalty, despite loss of exclusivity and cheap direct competition?
- Who are the future market leaders in the treatment of epilepsy?
- Which patient subgroups will have the largest impact on epilepsy sales?
- What are the drug companies’ strategies when penetrating a highly crowded market to achieve profitability?
- What are epilepsy’s unmet needs that could be addressed by drug companies?
Note: Product cover images may vary from those shown
2 of 3
FORECAST: EPILEPSY

- Executive Summary
- Market Overview and Trends
- Market Definition and Methodology
- Aptiom/Zebinix (eslicarbazepine)
- Fycompa (perampanel)
- Lyrica (pregabalin)
- Potiga/Trobalt (ezogabine/retigabine)
- Rikelta (brivaracetam)
- Vimpat (lacosamide)
- Primary Research Methodology

TREATMENT: EPILEPSY

- Executive Summary
- Primary Research Methodology
- Disease Definition and Diagnosis
- Patient Segmentation
- Current Treatment Options
- Treatment Dynamics
- Unmet Needs in Epilepsy

EPIDEMIOLOGY: EPILEPSY

- Executive Summary
- Disease Background
- Sources and Methodology
- Forecast
- Epidemiologist Insight
- Strengths and Limitations
- Appendix

MARKETED DRUGS: EPILEPSY

- Executive Summary
- Product Overview
- Other Marketed Drugs
- Product profile: Aptiom
- Product profile: Banzel
- Product profile: Briviact
- Product profile: Fycompa
- Product profile: Keppra and Keppra XR
- Product profile: Lamictal and Lamictal XR
- Product profile: Lyrica
- Product profile: Onfi
- Product profile: Potiga
- Product profile: Vimpat

PIPELINE: EPILEPSY

- Executive Summary
- Clinical Pipeline Overview
- Product profile (late stage): Epidiolex
- Product profile (late stage): ganaxolone
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll